biostudies-literatureBlanco-Blazquez VISCIIIInstituto de Salud Carlos IIIEuropean UnionJunta de Extremadura, Consejeria de Economía e InfraestructurasAgencia Estatal de InvestigaciónJunta de Extremadura, Consejería de Economía, Ciencia y Agenda Digital86https://www.ebi.ac.uk/biostudies/studies/S-EPMC9960949biostudies-literatureUnknown10(2)Therapy microencapsulation allows minimally invasive, safe, and effective administration. Hepatocyte growth factor (HGF) has angiogenic, anti-inflammatory, anti-apoptotic, and anti-fibrotic properties. Our objective was to evaluate the cardiac safety and effectiveness of intracoronary (IC) administration of HGF-loaded extended release microspheres in an acute myocardial infarction (AMI) swine model. An IC infusion of 5 × 10⁶ HGF-loaded microspheres (MS+HGF, <i>n</i> = 7), 5 × 10⁶ placebo microspheres (MS, <i>n</i> = 7), or saline (SAL, <i>n</i> = 7) was performed two days after AMI. TIMI flow and Troponin I (TnI) values were assessed pre- and post-treatment. Cardiac function was evaluated with magnetic resonance imaging (cMR) before injection and at 10 weeks. Plasma cJournal of cardiovascular development and diseaseIntracoronary Administration of Microencapsulated HGF in a Reperfused Myocardial Infarction Swine Model.PMC9960949PID2019-107329RAC22/AEI/10.13039/501100011033PI20/00247GR21201GR18199IB20191Martin HPalacios IGonzalez-Bueno IBlazquez RCrisostomo VSolares JCasado JGSteendam RBlanco-Blazquez VBaez-Diaz CUson ASanchez-Margallo FMfalseIntracoronary Administration of Microencapsulated HGF in a Reperfused Myocardial Infarction Swine Model.Therapy microencapsulation allows minimally invasive, safe, and effective administration. Hepatocyte growth factor (HGF) has angiogenic, anti-inflammatory, anti-apoptotic, and anti-fibrotic properties. Our objective was to evaluate the cardiac safety and effectiveness of intracoronary (IC) administration of HGF-loaded extended release microspheres in an acute myocardial infarction (AMI) swine model. An IC infusion of 5 × 10⁶ HGF-loaded microspheres (MS+HGF, <i>n</i> = 7), 5 × 10⁶ placebo microspheres (MS, <i>n</i> = 7), or saline (SAL, <i>n</i> = 7) was performed two days after AMI. TIMI flow and Troponin I (TnI) values were assessed pre- and post-treatment. Cardiac function was evaluated with magnetic resonance imaging (cMR) before injection and at 10 weeks. Plasma c2023-01-01T00:00:00Z2023 Feb2026-04-07T13:24:00.87Z2025-04-07T00:31:59.199ZS-EPMC99609493682658210.3390/jcdd10020086